John L Higgins Bio Techne Corp (TECH) insider trading activity

TECH Quotes by TradingView

John L Higgins is Director of BIO-TECHNE Corp. Currently has a direct ownership of 46,734 shares of TECH, which is worth approximately $3.49 Million. The most recent transaction as insider was on Sep 12, 2024, when has been sold 1,874 shares (Common Stock) at a price of $73.2 per share, resulting in proceeds of $137,176. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.7K
27.66% 3M change
33.59% 12M change
Total Value Held $3.49 Million

JOHN L HIGGINS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 12 2024
SELL
Payment of exercise price or tax liability
$137,176 $73.2 p/Share
1,874 Reduced 3.86%
46,734 Common Stock
Sep 12 2024
BUY
Exercise of conversion of derivative security
$137,700 $22.95 p/Share
6,000 Added 10.99%
48,608 Common Stock
Jul 08 2024
BUY
Exercise of conversion of derivative security
$137,700 $22.95 p/Share
6,000 Added 12.34%
42,608 Common Stock
May 14 2024
SELL
Open market or private sale
$335,360 $83.84 p/Share
4,000 Reduced 9.85%
36,608 Common Stock
May 14 2024
BUY
Exercise of conversion of derivative security
$91,800 $22.95 p/Share
4,000 Added 8.97%
40,608 Common Stock
Oct 26 2023
BUY
Grant, award, or other acquisition
-
1,625 Added 4.25%
36,608 Common Stock
Apr 28 2023
SELL
Payment of exercise price or tax liability
$349,634 $79.88 p/Share
4,377 Reduced 11.12%
34,983 Common Stock
Apr 28 2023
BUY
Exercise of conversion of derivative security
$349,600 $21.85 p/Share
16,000 Added 28.9%
39,360 Common Stock
Oct 27 2022
BUY
Grant, award, or other acquisition
-
338 Added 5.47%
5,840 Common Stock
Aug 11 2022
SELL
Open market or private sale
$196,142 $383.09 p/Share
512 Reduced 8.51%
5,502 Common Stock
Aug 10 2022
SELL
Open market or private sale
$749,669 $376.34 p/Share
1,992 Reduced 24.88%
6,014 Common Stock
Aug 10 2022
BUY
Exercise of conversion of derivative security
$227,460 $66.9 p/Share
3,400 Added 29.81%
8,006 Common Stock
Jun 08 2022
SELL
Open market or private sale
$219,654 $366.09 p/Share
600 Reduced 11.53%
4,606 Common Stock
Jun 08 2022
BUY
Exercise of conversion of derivative security
$40,140 $66.9 p/Share
600 Added 10.33%
5,206 Common Stock
Jun 07 2022
SELL
Open market or private sale
$364,310 $364.31 p/Share
1,000 Reduced 17.84%
4,606 Common Stock
Jun 07 2022
BUY
Exercise of conversion of derivative security
$66,900 $66.9 p/Share
1,000 Added 15.14%
5,606 Common Stock
Oct 28 2021
BUY
Grant, award, or other acquisition
-
194 Added 4.04%
4,606 Common Stock
Nov 06 2020
SELL
Open market or private sale
$1,499,800 $299.96 p/Share
5,000 Reduced 53.12%
4,412 Common Stock
Nov 06 2020
BUY
Exercise of conversion of derivative security
$351,750 $70.35 p/Share
5,000 Added 34.69%
9,412 Common Stock
Oct 29 2020
BUY
Grant, award, or other acquisition
-
391 Added 8.14%
4,412 Common Stock

Also insider at

LGND
LIGAND PHARMACEUTICALS INC Healthcare
Director
AHPAW
Avista Public Acquisition Corp. II Financial Services
Director
JLH

John L Higgins

Director
Emeryville, CA

Track Institutional and Insider Activities on TECH

Follow BIO-TECHNE Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TECH shares.

Notify only if

Insider Trading

Get notified when an Bio Techne Corp insider buys or sells TECH shares.

Notify only if

News

Receive news related to BIO-TECHNE Corp

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TECH